Glenmark Pharma Q4 net profit zooms to ₹301 crore; recommends 250% dividend

Glenmark Pharmaceuticals Ltd on Friday (May 29) reported a sharp surge in consolidated net profit to ₹301.4 crore in Q4 on the back of strong operational performance. The profit increased by over 6,400% from ₹4.6 crore a year earlier.

Revenue for the quarter rose 15.8% year-on-year to ₹3,770.5 crore, up from ₹3,256.2 crore. On a gross unit basis, EBITDA increased 35.9% to ₹762.5 crore from ₹561.1 crore. EBITDA margin expanded to 20.2% from 17.2% in the corresponding quarter of the previous year.

Glenmark Pharmaceuticals said its board has approved the transfer of the company’s nebuliser brands/IP portfolio to Glenmark Healthcare Ltd (GHL), a wholly owned subsidiary of the company.

ALSO READ | Glenmark’s US arm settles generic drug pricing case for $29.6 million

The transfer is expected to be carried out at a cash consideration of ₹223 crore based on an independent valuer's report. The agreement for the transfer is scheduled to be entered into on June 1, 2026, and is expected to be completed on or before June 30, 2026.

For the nine months ended December 31, 2025, the nebuliser business recorded revenue of ₹71.6 crore, representing about 1.3% of the company’s standalone revenue for the corresponding period. The net worth of the GHL business stood at negative ₹9.9 crore as on March 31, 2026.

Glenmark Healthcare Ltd is engaged in manufacturing pharmaceutical products, and the transaction qualifies as a related party transaction conducted at arm’s length. There will be no change in the shareholding pattern of Glenmark Pharmaceuticals following the transfer.

Also Read: Glenmark Pharma Q1 Results | Net profit plunges 86% to ₹47 crore despite stable revenue

The company said the nebuliser business segment is witnessing growth across India and emerging markets and that the transfer aims to enable sharper strategic focus and operational agility. GHL is also setting up a dedicated nebuliser manufacturing facility and will house a portfolio of innovative nebulisers, including a nebulised triple therapy for Chronic Obstructive Pulmonary Disease (COPD).

The company also recommended a dividend of 250%, translating to ₹2.5 per equity share of face value ₹1 each, for FY26. The dividend is subject to approval by shareholders at the upcoming annual general meeting.

Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,274.25, down by ₹108.40, or 4.55%, on the BSE today, May 29.

Also Read: Glenmark Pharma guides for 23% core margins in FY27